Premium
Posterior reversible encephalopathy syndrome induced by pazopanib for renal cell carcinoma
Author(s) -
Asaithambi G.,
Peters B. R.,
Hurliman E.,
Moran B. P.,
Khan A. S.,
Taylor R. A.
Publication year - 2013
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1111/jcpt.12031
Subject(s) - pazopanib , posterior reversible encephalopathy syndrome , medicine , renal cell carcinoma , encephalopathy , oncology , urology , pharmacology , magnetic resonance imaging , radiology , sunitinib
Summary What is known and Objective Posterior reversible encephalopathy syndrome ( PRES ) can be the result of acute hypertension, eclampsia, renal failure and the use of immunosuppressive or cytotoxic agents. We report a case of PRES as a result of the use of pazopanib, a vascular endothelial growth factor inhibitor used for renal cell carcinoma ( RCC ). Case summary A 76‐year‐old man treated with RCC develops PRES shortly after the initiation of pazopanib. What is new and conclusion There are no known reports of the association between PRES and pazopanib. We postulate that pazopanib can disrupt the normal endothelial function of the brain leading to the development of PRES .